RESUMEN
Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody drug conjugate MEN1309/OBT076 targeting CD205. The study included preclinical in vitro activity screening on a large panel of cell lines, both as single agent and in combination and validation experiments on in vivo models. CD205 was first shown frequently expressed in lymphomas, leukemias and multiple myeloma by immunohistochemistry on tissue microarrays. Anti-tumor activity of MEN1309/OBT076 as single agent was then shown across 42 B-cell lymphoma cell lines with a median IC50 of 200 pM and induction of apoptosis in 25/42 (59.5%) of the cases. The activity appeared highly correlated with its target expression. After in vivo validation as the single agent, the antibody drug conjugate synergized with the BCL2 inhibitor venetoclax, and the anti-CD20 monoclonal antibody rituximab. The first-in-class antibody drug targeting CD205, MEN1309/OBT076, demonstrated strong pre-clinical anti-tumor activity in lymphoma, warranting further investigations as a single agent and in combination.
Asunto(s)
Antineoplásicos , Inmunoconjugados , Linfoma , Anticuerpos Monoclonales/farmacología , Antígenos CD20 , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Apoptosis , Línea Celular Tumoral , Humanos , Inmunoconjugados/farmacología , Inmunoconjugados/uso terapéutico , Linfoma/tratamiento farmacológico , Rituximab/uso terapéuticoRESUMEN
CD205 is a type I transmembrane glycoprotein and is a member of the C-type lectin receptor family. Analysis by mass spectrometry revealed that CD205 was robustly expressed and highly prevalent in a variety of solid malignancies from different histotypes. IHC confirmed the increased expression of CD205 in pancreatic, bladder, and triple-negative breast cancer (TNBC) compared with that in the corresponding normal tissues. Using immunofluorescence microscopy, rapid internalization of the CD205 antigen was observed. These results supported the development of MEN1309/OBT076, a fully humanized CD205-targeting mAb conjugated to DM4, a potent maytansinoid derivate, via a cleavable N-succinimidyl-4-(2-pyridyldithio) butanoate linker. MEN1309/OBT076 was characterized in vitro for target binding affinity, mechanism of action, and cytotoxic activity against a panel of cancer cell lines. MEN1309/OBT076 displayed selective and potent cytotoxic effects against tumor cells exhibiting strong and low to moderate CD205 expression. In vivo, MEN1309/OBT076 showed potent antitumor activity resulting in durable responses and complete tumor regressions in many TNBC, pancreatic, and bladder cancer cell line-derived and patient-derived xenograft models, independent of antigen expression levels. Finally, the pharmacokinetics and pharmacodynamic profile of MEN1309/OBT076 was characterized in pancreatic tumor-bearing mice, demonstrating that the serum level of antibody-drug conjugate (ADC) achieved through dosing was consistent with the kinetics of its antitumor activity. Overall, our data demonstrate that MEN1309/OBT076 is a novel and selective ADC with potent activity against CD205-positive tumors. These data supported the clinical development of MEN1309/OBT076, and further evaluation of this ADC is currently ongoing in the first-in-human SHUTTLE clinical trial.
Asunto(s)
Inmunoconjugados/farmacología , Lectinas Tipo C/antagonistas & inhibidores , Terapia Molecular Dirigida/métodos , Neoplasias/tratamiento farmacológico , Receptores de Superficie Celular/antagonistas & inhibidores , Ensayos Antitumor por Modelo de Xenoinjerto/métodos , Animales , Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/farmacología , Antígenos CD/inmunología , Antígenos CD/metabolismo , Células CHO , Línea Celular Tumoral , Cricetulus , Femenino , Células HEK293 , Células HT29 , Humanos , Inmunoconjugados/química , Lectinas Tipo C/inmunología , Lectinas Tipo C/metabolismo , Células MCF-7 , Maitansina/química , Maitansina/farmacología , Ratones , Ratones Desnudos , Ratones SCID , Antígenos de Histocompatibilidad Menor/inmunología , Antígenos de Histocompatibilidad Menor/metabolismo , Neoplasias/metabolismo , Neoplasias/patología , Receptores de Superficie Celular/inmunología , Receptores de Superficie Celular/metabolismoRESUMEN
Antibody-based immunotherapy represents a promising strategy to eliminate chemorefractory leukemic cells in acute myeloid leukemia (AML). In this study, we evaluated a novel Fc-engineered antibody against CD157 (MEN1112) for its suitability as immunotherapy in AML. CD157 was expressed in 97% of primary AML patient samples. A significant, albeit lower expression level of CD157 was observed within the compartment of leukemia-initiating cells, which are supposed to be the major source of relapse. In healthy donor bone marrow, CD157 was expressed on CD34+ cells. In ex vivo assays, MEN1112 triggered natural killer (NK) cell-mediated cytotoxicity against AML cell lines and primary AML cells. Compared to its parental analogue, the Fc-engineered antibody exhibited higher antibody dependent cellular cytotoxicity responses. Using NK cells from AML patients, we observed heterogeneous MEN1112-mediated cytotoxicity against AML cells, most likely due to well-documented defects in AML-NK cells and corresponding inter-patient variations in NK cell function. Cytotoxicity could not be correlated to the time after completion of chemotherapy. In summary, we could demonstrate that CD157 is strongly expressed in AML. MEN1112 is a promising antibody construct that showed high cytotoxicity against AML cells and warrants further clinical testing. Due to variability in NK-cell function of AML patients, the time of application during the course of the disease as well as combinatorial strategies might influence treatment results.
Asunto(s)
ADP-Ribosil Ciclasa/antagonistas & inhibidores , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/metabolismo , Terapia Molecular Dirigida , Proteínas Recombinantes de Fusión/uso terapéutico , ADP-Ribosil Ciclasa/genética , ADP-Ribosil Ciclasa/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Citotoxicidad Celular Dependiente de Anticuerpos , Antígenos CD/genética , Antígenos CD/metabolismo , Biomarcadores de Tumor , Línea Celular Tumoral , Femenino , Citometría de Flujo , Proteínas Ligadas a GPI/antagonistas & inhibidores , Proteínas Ligadas a GPI/genética , Proteínas Ligadas a GPI/metabolismo , Expresión Génica , Células Madre Hematopoyéticas/efectos de los fármacos , Células Madre Hematopoyéticas/metabolismo , Humanos , Células Asesinas Naturales/inmunología , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/inmunología , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
An insight into protein mechanisms involved in disease is critical to the discovery and design of new therapeutic tools. Direct protein analysis provides a method for studying the proteome of a tissue irrespective of an in-depth knowledge of its transcriptome. The development of a human central nervous system (CNS) proteome database ultimately will serve to accelerate the development of specific diagnostic and prognostic markers, neuropsychiatric disease markers, and the corresponding therapeutic tools. It may also reduce the uncertainties in in silico gene predictions by direct open reading frame verification and the ambiguities that experimental models of disease may provide. Advances in gel independent proteomic analyses by solid phase isotope tagging provide greater scope for the characterization of previously elusive membrane proteins; approximately half of all drug targets are key CNS membrane proteins. These advances hold great promise for improvements in the understanding, diagnosis, and therapy of central nervous system disorders.
Asunto(s)
Sistema Nervioso Central/metabolismo , Trastornos Mentales/metabolismo , Proteómica/tendencias , Bases de Datos de Proteínas/tendencias , Genotipo , Humanos , Trastornos Mentales/diagnóstico , Trastornos Mentales/terapia , Fenotipo , Transducción de SeñalRESUMEN
Since the publication of the human genome, two key points have emerged. First, it is still not certain which regions of the genome code for proteins. Second, the number of discrete protein-coding genes is far fewer than the number of different proteins. Proteomics has the potential to address some of these postgenomic issues if the obstacles that we face can be overcome in our efforts to combine proteomic and genomic data. There are many challenges associated with high-throughput and high-output proteomic technologies. Consequently, for proteomics to continue at its current growth rate, new approaches must be developed to ease data management and data mining. Initiatives have been launched to develop standard data formats for exchanging mass spectrometry proteomic data, including the Proteomics Standards Initiative formed by the Human Proteome Organization. Databases such as SwissProt and Uniprot are publicly available repositories for protein sequences annotated for function, subcellular location and known potential post-translational modifications. The availability of bioinformatics solutions is crucial for proteomics technologies to fulfil their promise of adding further definition to the functional output of the human genome. The aim of the Oxford Genome Anatomy Project is to provide a framework for integrating molecular, cellular, phenotypic and clinical information with experimental genetic and proteomics data. This perspective also discusses models to make the Oxford Genome Anatomy Project accessible and beneficial for academic and commercial research and development.
Asunto(s)
Bases de Datos de Proteínas , Genoma Humano , Proteoma/química , Proteómica/tendencias , Genómica , Humanos , Espectrometría de Masa por Láser de Matriz Asistida de Ionización DesorciónRESUMEN
The discovery, design and evaluation of new medicines is critically dependent on the elucidation of protein mechanisms involved in human diseases. Since the proteome of a cell or tissue is not a simple reflection of its transcriptome, direct protein-based analysis is needed. Advances in proteomic technologies are improving the analysis of membrane proteins and signaling complexes with increased speed and molecular detail. Changes in protein isoforms due to post-translational modifications, such as phosphorylation induced by cell signaling events and alternative splice forms of receptors, may be mapped to an altered protein expression pattern in clinically relevant cell populations with a causative or diagnostic disease link. A CNS proteome database derived from primary human tissues may avoid ambiguities of experimental models. It will also accelerate the development of more specific diagnostic and prognostic disease markers as well as new selective therapeutics. Proteomics is also being applied to resolve in silico gene prediction uncertainties by direct open reading frame verification. These advances hold great promise for improvements in the understanding, diagnosis and therapy of central nervous system disorders.
Asunto(s)
Enfermedades del Sistema Nervioso Central/diagnóstico , Proteoma/análisis , Proteómica/métodos , Biomarcadores/análisis , Enfermedades del Sistema Nervioso Central/enzimología , Enfermedades del Sistema Nervioso Central/fisiopatología , Predicción , Genoma Humano , Genotipo , Humanos , Proteínas de la Membrana/química , Proteínas de la Membrana/aislamiento & purificación , Proteínas de la Membrana/fisiología , Modelos Biológicos , Sistemas de Lectura Abierta , Fenotipo , Isoformas de Proteínas/análisis , Isoformas de Proteínas/química , Transducción de SeñalRESUMEN
The mRNA levels of hyal-1, hyal-2, LUCA3 and PH20, the 4 hyaluronidases with demonstrated endoglucosaminidase activity, were extensively profiled in normal and tumor tissues and cell lines, using dot blot analysis and quantitative PCR. In normal tissues, hyal-1, hyal-2 and LUCA3 all showed unique patterns of mRNA expression, but were generally of widespread distribution, whereas PH20 mRNA was restricted to testes. In a small set of breast tumor samples, no elevations in hyal-1, hyal-2 or LUCA3 mRNA were seen. Hyaluronidase activity measured by a novel assay or zymography was also not elevated in sera from a number of breast cancer patients, compared to sera from normal volunteers. In ex vivo xenograft tumor cell lines, however, hyal-1 or hyal-2 mRNA levels were frequently elevated, whereas LUCA3 was only infrequently elevated and PH20 not at all. Two cell lines were engineered to overexpress hyal-1: a breast cancer line (CAL51) and a prostate cancer line (PC3M). Although the in vitro properties of the hyal-1 overexpressing cell lines were indistinguishable from the parental cells, the orthotopic growth of hyal-1 expressing PC3M cells in nu/nu mice resulted in significantly increased numbers of metastases, supportive of a role for hyal-1 in extravasation and metastatic tumor formation in this model of prostate cancer.